Results 251 to 260 of about 87,437 (368)

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Cancer Research, 2018
T. Pardee, Rebecca G. Anderson, K. Pladna, S. Isom, Lais P. Ghiraldeli, L. Miller, J. Chou, G. Jin, Wei Zhang, L. Ellis, Dmitriy Berenzon, D. Howard, D. Hurd, M. Manuel, S. Dralle, S. Lyerly, B. Powell   +16 more
semanticscholar   +1 more source

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population‐based study

British Journal of Haematology, Volume 207, Issue 4, Page 1366-1376, October 2025.
In a nationwide cohort study, 873 patients with mantle cell lymphoma (MCL) were followed for a median of 7 years. During follow‐up, 28 patients developed secondary central nervous system (CNS) lymphoma (SCNSL) with a 5‐year cumulative incidence of 2.8% (95% confidence interval [CI] 1.7–3.9).
Trine Trab, Torgerð Ranadóttir, Iman Chanchiri, Ahmed Ludvigsen Al‐Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Laura Mors Haunstrup, Gabriella Cunsolo, Christian Bjørn Poulsen, Thomas Stauffer Larsen, Simon Husby, Peter Brown, Eliza A. Hawkes, Tarec C. El‐Galaly, Kirsten Grønbæk   +15 more
wiley   +1 more source

Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. [PDF]

Hemasphere
Thieblemont C, Gomes Da Silva M, Leppä S, Lenz G, Cottereau AS, Fox C, Lopez-Guillermo A, Illidge T, Jurczak W, Eich H, Aurer I, Trneny M, Rosenwald AA, Davies A, Zwezerijnen BG, Bolanos N, Marković M, Jais JP, Broussais F, Dreyling M, Vitolo U, Tilly H, Kersten MJ.   +22 more
europepmc   +1 more source

The Mechanism of Synergistic Interaction between Etoposide and Cytarabine

, 2002
Kazuya Ooi
openalex   +2 more sources

Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate‐cytarabine regimen [PDF]

, 2004
Abdullah Büyükçelik, Bülent Yalçın, Güngör Utkan, Hatice Doruk   +3 more
openalex   +1 more source

Class 3 MAPK Mutation in Langerhans cell histiocytosis and Trametinib—Reporting Two Contrarian Responses

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
Natalia Wojciechowska, Alejandra Cervantes‐Dominguez, Jason Wang, Anish Ray   +3 more
wiley   +1 more source

Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma

British Journal of Haematology, Volume 207, Issue 4, Page 1484-1494, October 2025.
Summary Chimeric antigen receptor (CAR) T‐cell therapy is effective for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain.
Suguru Morimoto, Tomoyasu Jo, Toshio Kitawaki, Takashi Sakamoto, Chisaki Mizumoto, Junya Kanda, Momoko Nishikori, Kouhei Yamashita, Miki Nagao, Akifumi Takaori‐Kondo, Yasuyuki Arai   +10 more
wiley   +1 more source

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs. [PDF]

Cancer
Burton H, Boussi L, Nemirovsky D, Derkach A, Ciervo J, Famulare C, Chin KK, Valtis Y, Yisraeli Salman M, Patel K, Shah GL, Goldberg AD, Geyer MB, Thompson MC, Tallman MS, Stein EM, Cai SF.   +16 more
europepmc   +1 more source

Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

European Journal of Haematology, Volume 115, Issue 4, Page 391-402, October 2025.
ABSTRACT Chimeric antigen receptor T‐cell therapy (CART) has replaced salvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation (HDT‐ASCT) as the preferred second‐line treatment for early relapsed (< 12 months) large B‐cell lymphoma (LBCL).
Hilde T. van der Galiën, Hilde A. M. Kooistra, Robby Kibbelaar, Nic J. G. M. Veeger, Marcel Nijland, Gerwin Huls, Tom van Meerten, Rozemarijn S. van Rijn, on behalf of The Hemobase Population Registry Consortium, Gerrit Jan Veldhuis, Gerhard Woolthuis, Leonie van der Burg, Bas van Rees, Mels Hoogendoorn, Bas Franken, Esther de Waal, Rozemarijn van Rijn, Peter Joosten, Hilde van der Galiën, Eric van Roon, Sjoerd Hovenga, Frank Schipper, Harmen van Kamp, Adrian Kruit, Huib Storm, Harry de Wit, Willeke Ferket‐Franken, Wilma Smit, Renske Vlasman, Robby Kibbelaar, Roy Jurhill, Sophie Dijkhuizen, Elise van der Logt, Melvin Kilsdonk   +33 more
wiley   +1 more source

Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study. [PDF]

Front Immunol
Wang W, Wang B, Sun Y, Qiu L, Qian Z, Zhou S, Song Z, Li W, Zhang X, Li L, Wang X, Zhang H.   +11 more
europepmc   +1 more source